Related Experiment Video
Updated: Jul 1, 2025

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Ticagrelor Induced Cheyne-Stokes Respiration and Asystolic Ventricular Standstill: A Case Report
Bektaş Murat1, Selda Murat2, Eylem Kivanc1
1Eskisehir City Hospital.
Insights
Ticagrelor, a P2Y12 inhibitor, effectively reduces adverse events in acute coronary syndrome (ACS). However, rare cases show potential for serious bradyarrhythmias like asystolic ventricular standstill.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ticagrelor is a reversible P2Y12 inhibitor used for acute coronary syndrome (ACS).
- It demonstrates superior efficacy over clopidogrel in reducing major adverse events.
- Commonly reported side effects include dyspnea and bradyarrhythmia.
Observation:
- Previous studies indicated ticagrelor's bradyarrhythmic potential is transient and clinically insignificant.
- This report details a rare case of ticagrelor-associated Cheyne-Stokes respiration and asystolic ventricular standstill.
- The patient experienced cardiac arrest requiring resuscitation and temporary pacemaker insertion.
Findings:
- Ticagrelor can be associated with severe bradyarrhythmic events, including asystolic ventricular standstill.
- These events may necessitate immediate medical intervention, such as resuscitation and temporary pacing.
- The findings challenge the notion that ticagrelor's bradyarrhythmic risks are always transient and clinically insignificant.
Implications:
- Clinicians should maintain a high index of suspicion for severe bradyarrhythmia in ACS patients treated with ticagrelor.
- Careful patient monitoring is crucial, especially during the acute initiation phase.
- Further investigation into the mechanisms and risk factors for severe ticagrelor-associated bradyarrhythmias is warranted.
Abstract:
Ticagrelor is a potent, direct-acting, and reversible P2Y12‑adenosine diphosphate receptor blocker. It has a rapid onset of action and an intense and consistent platelet reactivity inhibition that has been demonstrated to be superior to clopidogrel in decreasing major adverse events in acute coronary syndrome (ACS). Although ticagrelor is well tolerated in ACS patients, it has side effects, such as dyspnea and bradyarrhythmia, as reported in the Platelet Inhibition and Patient Outcomes (PLATO) study. Furthermore, it was reported that ticagrelor's bradyarrhythmic potential was transient and not clinically significant beyond the acute initiation phase. Nor was there a difference in rates of syncope or need for pacemaker insertion during 30 days of follow-up. Here we report a case of ticagrelor associated with Cheyne-Stokes respiration and asystolic ventricular standstill in a patient with ACS who required resuscitation and insertion of a temporary pacemaker.
More Related Videos
10:17Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
Related Concept Videos
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Electrocardiogram
Three major waveforms are present in a typical ECG recording: the P wave, the QRS complex, and...
Alterations in Respiration II
In Biot's breathing, the respiratory rate and depth are irregular, alternating between periods of deep gasping and apnea. Common causes...
Depolarizing Blockers: Mechanism of Action
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Cardiac Action Potential
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
Depolarizing Blockers: Pharmocokinetics